This company has been marked as potentially delisted and may not be actively trading. Range Cancer Therapeutics ETF (CNCR) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisHoldingsRatingsShort InterestTrendsBuy This Stock Range Cancer Therapeutics ETF Short Interest DataRange Cancer Therapeutics ETF (CNCR) has a short interest of 6,800 shares, representing 0.87% of the float (the number of shares available for trading by the public). This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 2.4, indicating that it would take 2.4 days of the average trading volume of 4,836 shares to cover all short positions.Current Short Interest6,800 sharesPrevious Short Interest6,800 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$64,328.00Short Interest Ratio2.4 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares780,814 sharesShort Percent of Float0.87%Today's Trading Volume1,757 sharesAverage Trading Volume4,836 sharesToday's Volume Vs. Average36% Short Selling Range Cancer Therapeutics ETF? Sign up to receive the latest short interest report for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCNCR Short Interest Over TimeCNCR Days to Cover Over TimeCNCR Percentage of Float Shorted Over Time Range Cancer Therapeutics ETF Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20256,800 shares $64,328.00 No Change0.9%2.4 $9.46 3/15/20256,800 shares $72,970.80 +6.3%0.9%2.1 $10.73 2/28/20256,400 shares $72,825.60 -1.5%0.8%1.8 $11.38 2/15/20256,500 shares $82,290.00 +1.6%0.6%1.9 $12.66 1/31/20256,400 shares $78,912.00 -4.5%N/A1.9 $12.33 1/15/20256,700 shares $76,483.85 +28.9%N/A1.9 $11.42 12/31/20245,200 shares $63,284.00 +4.0%N/A1.4 $12.17 12/15/20245,000 shares $63,400.00 +28.2%N/A1.5 $12.68 11/30/20243,900 shares $55,965.00 +18.2%N/A1.1 $14.35 11/15/20243,300 shares $44,187.00 +94.1%N/A0.9 $13.39 Get the Latest News and Ratings for CNCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. 10/31/20241,700 shares $24,786.00 +1,600.0%N/A0.4 $14.58 10/15/2024100 shares $1,506.00 -75.0%N/A0 $15.06 9/30/2024400 shares $5,980.00 -76.5%N/A0.1 $14.95 9/15/20241,700 shares $27,387.00 +1,600.0%N/A0.3 $16.11 8/31/2024100 shares $1,508.00 -94.7%N/A0 $15.08 8/15/20241,900 shares $26,980.00 +5.6%N/A0.3 $14.20 7/31/20241,800 shares $27,540.00 -74.3%N/A0.2 $15.30 7/15/20247,000 shares $107,450.00 +62.8%N/A0.8 $15.35 6/30/20244,300 shares $58,071.50 -42.7%N/A0.3 $13.51 6/15/20247,500 shares $107,025.00 -25.7%N/A0.5 $14.27 5/31/202410,100 shares $146,450.00 -58.9%N/A0.3 $14.50 5/15/202424,600 shares $374,904.00 +748.3%N/A0.7 $15.24 4/30/20242,900 shares $42,804.00 -79.1%N/A0.1 $14.76 4/15/202413,900 shares $208,639.00 -50.2%N/A0.4 $15.01 3/31/202427,900 shares $463,698.00 -59.2%N/A0.8 $16.62 3/15/202468,300 shares $1.11 million +73.4%N/A2.1 $16.26 2/29/202439,400 shares $680,438.00 +47.0%N/A2.6 $17.27 2/15/202426,800 shares $429,738.00 +538.1%N/A2.9 $16.04 1/31/20244,200 shares $59,472.00 No ChangeN/A0.8 $14.16 5/15/2023100 shares $1,374.00 -92.9%N/A0 $13.74 4/30/20231,400 shares $17,707.90 -44.0%N/A0.2 $12.65 4/15/20232,500 shares $31,025.00 +257.1%N/A0.4 $12.41 3/31/2023700 shares $8,393.00 +16.7%N/A0.1 $11.99 3/15/2023600 shares $7,494.00 -78.6%N/A0.2 $12.49 2/28/20232,800 shares $37,660.00 -47.2%N/A0.8 $13.45 2/15/20235,300 shares $75,366.00 -38.4%N/A1.5 $14.22 1/31/20238,600 shares $127,710.00 -4.4%N/A2.5 $14.85 1/15/20239,000 shares $132,750.00 +5.9%N/A1.4 $14.75 12/30/20228,500 shares $116,705.00 -35.6%N/A1.3 $13.73 12/15/202213,200 shares $200,376.00 +12.8%N/A1.4 $15.18Warning: “DOGE Collapse” imminent (Ad)Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.Click here to see what they’re predicting now. 11/30/202211,700 shares $174,447.00 +9.4%N/A1.3 $14.91 11/15/202210,700 shares $165,743.00 -23.0%N/A1.2 $15.49 10/31/202213,900 shares $208,500.00 +0.7%N/A1.5 $15.00 10/15/202213,800 shares $201,894.00 No ChangeN/A2.1 $14.63 9/30/202212,700 shares $183,134.00 -21.1%N/A1.7 $14.42 9/15/202216,100 shares $260,820.00 +3.9%N/A3 $16.20 8/31/202215,500 shares $240,405.00 -15.8%N/A2.2 $15.51 8/15/202218,400 shares $330,832.00 +13.6%N/A2.5 $17.98 7/31/202216,200 shares $259,200.00 -12.0%N/A2.1 $16.00 7/15/202218,400 shares $304,704.00 -27.0%N/A2.4 $16.56 6/30/202225,200 shares $382,788.00 -2.0%N/A3.8 $15.19 6/15/202225,700 shares $345,022.50 +26.0%N/A3.7 $13.43 5/31/202220,400 shares $283,941.48 +23.6%N/A3.9 $13.92 5/15/202216,500 shares $236,445.00 +17.0%N/A3.4 $14.33 4/30/202214,100 shares $218,225.70 -6.0%N/A3.1 $15.48 4/15/202215,000 shares $264,150.00 -8.5%N/A2.1 $17.61 3/31/202216,400 shares $297,332.00 -13.7%N/A1.9 $18.13 3/15/202219,000 shares $311,790.00 +36.7%N/A2.3 $16.41 2/28/202213,900 shares $255,760.00 -30.5%N/A1.6 $18.40 2/15/202220,000 shares $372,020.00 +48.2%N/A2.2 $18.60 1/31/202213,500 shares $247,847.85 +5.5%N/A1.5 $18.36 1/15/202212,800 shares $261,120.00 +1,728.6%N/A1.9 $20.40 12/31/2021700 shares $17,037.30 -50.0%N/A0.1 $24.34 12/15/20211,400 shares $34,716.36 -6.7%N/A0.3 $24.80 11/30/20211,500 shares $40,320.00 +150.0%N/A0.3 $26.88 11/15/2021600 shares $17,136.00 -14.3%N/A0.1 $28.56 10/29/2021700 shares $20,189.19 +16.7%N/A0.1 $28.84 10/15/2021600 shares $17,514.00 -33.3%N/A0.1 $29.19 9/30/2021900 shares $27,837.00 +50.0%N/A0.2 $30.93 9/15/2021600 shares $18,552.00 No ChangeN/A0.1 $30.92 8/31/2021600 shares $18,336.00 -64.7%N/A0.1 $30.56 8/13/20211,700 shares $48,909.00 No ChangeN/A0.3 $28.77 7/30/20211,700 shares $50,405.00 -48.5%N/A0.3 $29.65 7/15/20213,300 shares $97,350.00 -2.9%N/A0.6 $29.50 6/30/20213,400 shares $108,426.00 +13.3%N/A0.5 $31.89 6/15/20213,000 shares $91,860.00 +11.1%N/A0.4 $30.62 5/28/20212,700 shares $82,593.00 +28.6%N/A0.4 $30.59 5/14/20212,100 shares $60,480.00 +10.5%N/A0.3 $28.80 4/30/20211,900 shares $58,862.00 -74.7%N/A0.3 $30.98 4/15/20217,500 shares $218,250.00 +17.2%N/A1 $29.10 3/31/20216,400 shares $185,920.00 +25.5%N/A0.8 $29.05 3/15/20215,100 shares $163,149.00 No ChangeN/A0.6 $31.99 2/26/20215,100 shares $159,120.00 -60.8%N/A0.5 $31.20 2/12/202113,000 shares $449,686.90 +3.2%N/A1.2 $34.59 1/29/202112,600 shares $411,982.20 +215.0%N/A1.2 $32.70 1/15/20214,000 shares $139,985.20 No ChangeN/A0.4 $35.00 CNCR Short Interest - Frequently Asked Questions What is Range Cancer Therapeutics ETF's current short interest? Short interest is the volume of Range Cancer Therapeutics ETF shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 6,800 shares of CNCR short. 0.87% of Range Cancer Therapeutics ETF's shares are currently sold short. Learn More on Range Cancer Therapeutics ETF's current short interest. What is a good short interest ratio for Range Cancer Therapeutics ETF? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CNCR shares currently have a short interest ratio of 2.0. Learn More on Range Cancer Therapeutics ETF's short interest ratio. What is a good short interest percentage for Range Cancer Therapeutics ETF? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.87% of Range Cancer Therapeutics ETF's floating shares are currently sold short. How does Range Cancer Therapeutics ETF's short interest compare to its competitors? 0.87% of Range Cancer Therapeutics ETF's shares are currently sold short. Here is how the short interest of companies compare to Range Cancer Therapeutics ETF: JPMorgan Healthcare Leaders ETF (0.31%), ProShares UltraShort Nasdaq Biotechnology (4.15%), First Trust Nasdaq Pharmaceuticals ETF (0.13%), Invesco Nasdaq Biotechnology ETF (0.14%), ProShares Ultra Nasdaq Biotechnology (0.14%), Invesco Dorsey Wright Healthcare Momentum ETF (0.18%), VanEck Biotech ETF (0.06%), VanEck Pharmaceutical ETF (41.19%), and iShares Biotechnology ETF (21.22%). Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Range Cancer Therapeutics ETF stock? Short selling CNCR is an investing strategy that aims to generate trading profit from Range Cancer Therapeutics ETF as its price is falling. CNCR shares are trading down $1.56 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Range Cancer Therapeutics ETF? A short squeeze for Range Cancer Therapeutics ETF occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CNCR, which in turn drives the price of the stock up even further. How often is Range Cancer Therapeutics ETF's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNCR, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies JPMorgan Healthcare Leaders ETF Short Interest Data ProShares UltraShort Nasdaq Biotechnology Short Interest Data First Trust Nasdaq Pharmaceuticals ETF Short Interest Data Invesco Nasdaq Biotechnology ETF Short Interest Data ProShares Ultra Nasdaq Biotechnology Short Interest Data Invesco Dorsey Wright Healthcare Momentum ETF Short Interest Data VanEck Biotech ETF Short Interest Data VanEck Pharmaceutical ETF Short Interest Data iShares Biotechnology ETF Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CNCR) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
